AI Summary
We reviewed 12 live results for ruxience (rituximab) and narrowed them down to the 3 options that look most worth comparing first.
The strongest themes across this short list are Oncology and Pharmaceuticals.
Comparison Table
Recommended
Ruxience (rituximab-pvvr)
Source: Pfizer Inc.
Description
Ruxience is a biosimilar to the reference product Rituxan (rituximab). It is a prescription biological medicine used for the treatment of adults with Non-Hodgkin’s Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Rheumatoid Arthritis (RA), Granulomatosis with Polyangiitis (GPA), and Microscopic Polyangiitis (MPA). Administered via intravenous infusion, it is available in 100 mg/10 mL or 500 mg/50 mL single-dose vials. As a monoclonal antibody, it works by targeting the CD20 antigen on the surface of B-cells, facilitating their destruction by the immune system.
Best for
oncology patients, rheumatoid arthritis management, biosimilar therapeutic options and hematologic malignancies
View Details
Rating
Ruxience
Source: Pfizer Private Limited (Singapore)
Description
Ruxience is a rituximab biosimilar (referencing Rituxan/MabThera) approved for use in Singapore. It is used to treat adult patients with certain types of non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and other autoimmune conditions.
Best for
lymphoma treatment, leukemia patients and autoimmune disease care
View Details
Rating
Ruxience (Rituximab)
Source: Pfizer Philippines Inc.
Description
Ruxience is a biosimilar used for the treatment of Non-Hodgkin’s Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), and rheumatoid arthritis.
Best for
Non-Hodgkin’s Lymphoma, Chronic Lymphocytic Leukemia and rheumatoid arthritis patients
View Details
Rating
| Compare | Ruxience (rituximab-pvvr) | Ruxience | Ruxience (Rituximab) |
|---|---|---|---|
| Source | Pfizer Inc. | Pfizer Private Limited (Singapore) | Pfizer Philippines Inc. |
| Description | Ruxience is a biosimilar to the reference product Rituxan (rituximab). It is a prescription biological medicine used for the treatment of adults with Non-Hodgkin’s Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Rheumatoid Arthritis (RA), Granulomatosis with Polyangiitis (GPA), and Microscopic Polyangiitis (MPA). Administered via intravenous infusion, it is available in 100 mg/10 mL or 500 mg/50 mL single-dose vials. As a monoclonal antibody, it works by targeting the CD20 antigen on the surface of B-cells, facilitating their destruction by the immune system. | Ruxience is a rituximab biosimilar (referencing Rituxan/MabThera) approved for use in Singapore. It is used to treat adult patients with certain types of non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and other autoimmune conditions. | Ruxience is a biosimilar used for the treatment of Non-Hodgkin’s Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), and rheumatoid arthritis. |
| Best for | oncology patients, rheumatoid arthritis management, biosimilar therapeutic options and hematologic malignancies | lymphoma treatment, leukemia patients and autoimmune disease care | Non-Hodgkin’s Lymphoma, Chronic Lymphocytic Leukemia and rheumatoid arthritis patients |
| Tags | |||
| Action | View Details | View Details | View Details |
| Rating |
AI Recommendation
If you want the most balanced option to start with, I recommend:
"Ruxience (rituximab-pvvr) from Pfizer Inc.."
I picked this because Ruxience is a highly regulated biosimilar approved by the FDA and registered with Malaysia's NPRA, offering a clinically equivalent but often more accessible alternative to the original biologic for cancer and autoimmune treatments.
Share this search
Related Finds